8-K: Protagonist Therapeutics' Icotrokinra Shows Promise in Psoriasis and Ulcerative Colitis Trials

Protagonist Therapeutics announces positive clinical study results for icotrokinra in both plaque psoriasis and ulcerative colitis, suggesting a potential shift in treatment paradigms.

Summary

• Protagonist Therapeutics announced positive results for icotrokinra (JNJ-2113) in Phase 3 trials for plaque psoriasis and Phase 2b trials for ulcerative colitis.
• In the ICONIC-LEAD psoriasis study, nearly half of patients achieved completely clear skin (IGA 0) at Week 24.
• 65% of patients achieved an IGA score of 0/1 (clear or almost clear skin) and 50% achieved a PASI 90 response at Week 16, compared to 8% and 4% in the placebo group.
• The ICONIC-ADVANCE 1&2 studies met co-primary endpoints of IGA 0/1 and PASI 90 versus placebo at Week 16 and showed superiority to deucravacitinib.
• Johnson & Johnson is initiating the ICONIC-ASCEND study, a head-to-head trial comparing icotrokinra to ustekinumab.
• In the ANTHEM-UC ulcerative colitis study, all three doses of icotrokinra met the primary endpoint of clinical response at Week 12.
• The highest dose achieved a 63.5% clinical response rate at Week 12 versus 27.0% for placebo.
• 30.2% of patients on the highest dose achieved clinical remission at Week 12 versus 11.1% for placebo.
• Clinical remission and response rates in the ANTHEM-UC study continued to improve through Week 28.
• Icotrokinra was well-tolerated in both psoriasis and ulcerative colitis studies, with similar adverse event rates between treatment and placebo groups.

Sentiment

Score: 9

Explanation: The document presents overwhelmingly positive clinical trial results for icotrokinra in both psoriasis and ulcerative colitis, suggesting a strong potential for the drug to become a significant player in these markets. The initiation of a head-to-head study against ustekinumab further boosts confidence in the drug's prospects.

Positives

• Icotrokinra demonstrated high efficacy in treating plaque psoriasis, with significant skin clearance and superiority to deucravacitinib.
• The drug showed promising results in treating ulcerative colitis, with high clinical response and remission rates.
• Icotrokinra has a favorable safety profile in both psoriasis and ulcerative colitis studies.
• The drug is administered orally, offering a more convenient treatment option compared to injectable biologics.
• Johnson & Johnson is further investing in icotrokinra's development through head-to-head studies and advanced clinical trials.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including the ability to develop and commercialize product candidates, the ability to earn milestone payments under collaboration agreements, and the ability to obtain and maintain regulatory approval of product candidates.
• The company operates in a competitive industry and competes successfully against competitors that have greater resources.
• The company's ability to obtain and adequately protect intellectual property rights for product candidates.

Future Outlook

Protagonist anticipates further progression of icotrokinra into more advanced clinical studies in ulcerative colitis and Crohn's disease, as well as New Drug Application submissions to the FDA for icotrokinra and rusfertide in 2025.

Management Comments

• Dinesh V. Patel, Ph.D., President and Chief Executive Officer at Protagonist, stated that icotrokinra offers a standout combination of complete skin clearance and favorable safety profile in a once-daily pill for psoriasis.
• Dinesh V. Patel, Ph.D., President and Chief Executive Officer at Protagonist, stated that the ANTHEM Phase 2 ulcerative colitis study results broaden the potential utility of icotrokinra from psoriasis to inflammatory bowel diseases.

Industry Context

The announcement positions icotrokinra as a potential competitor to existing treatments for psoriasis and ulcerative colitis, including both oral and injectable therapies. The head-to-head study against ustekinumab is particularly significant, as it could establish icotrokinra as a superior option in the market.

Comparison to Industry Standards

• Deucravacitinib (Sotyktu) is an oral TYK2 inhibitor approved for psoriasis, and icotrokinra's superiority to deucravacitinib in the ICONIC-ADVANCE studies suggests a potential advantage.
• Ustekinumab (Stelara) is an injectable IL-12/23 inhibitor widely used for psoriasis and ulcerative colitis; the ICONIC-ASCEND study will directly compare icotrokinra's efficacy to ustekinumab.
• Vedolizumab (Entyvio) is an injectable biologic used for ulcerative colitis; icotrokinra's Phase 2b results suggest it could become a competitive oral alternative.
• Ozanimod (Zeposia) is an oral S1P receptor modulator approved for ulcerative colitis; the ANTHEM-UC study included patients who had an inadequate response or intolerance to ozanimod, suggesting a potential role for icotrokinra in this population.

Stakeholder Impact

• Shareholders may see increased value due to the positive clinical trial results and potential market opportunities for icotrokinra.
• Patients with psoriasis and ulcerative colitis may benefit from a new, effective, and convenient oral treatment option.
• Employees of Protagonist Therapeutics and Johnson & Johnson may experience increased job security and growth opportunities due to the success of icotrokinra.
• The collaboration between Protagonist and Johnson & Johnson is strengthened by the positive results, potentially leading to further collaborations.

Next Steps

• Johnson & Johnson will initiate the Phase 3 ICONIC-ASCEND study comparing icotrokinra to ustekinumab.
• Comprehensive results from the ANTHEM-UC study are being prepared for presentation at upcoming medical congresses.
• Protagonist expects to submit New Drug Applications to the FDA for icotrokinra and rusfertide in 2025.
• Icotrokinra will progress into more advanced clinical studies in ulcerative colitis and Crohn's disease.

Key Dates